Advanced CRISPR System Using Al3Cas12f Enzyme Achieves 90 Percent Gene Editing Efficiency in Human Cells

A research team has developed an advanced CRISPR gene-editing system capable of achieving targeted delivery within the human body, marking a significant step toward expanded clinical applications. The researchers identified a naturally occurring enzyme, Al3Cas12f, which is small enough to be incorporated into adeno-associated virus (AAV) vectors—a widely used method for delivering gene therapies. They subsequently engineered an enhanced version of this enzyme that demonstrated up to 90% efficiency in editing genes within human cells.

The study highlights the potential of Al3Cas12f as a compact and effective tool for in-body gene editing. Its size allows it to fit into AAV vectors, which are commonly employed due to their ability to target specific tissues with precision. By optimizing the enzyme’s performance, the researchers significantly improved its functionality in human cells, addressing challenges associated with earlier CRISPR systems that were too large or inefficient for certain therapeutic applications. This development could pave the way for more accessible and precise gene-editing treatments in the future.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 13, 2026

Author

GOAI